Liminatus Pharma, Inc. Class A Common Stock
LIMN
Get informed when a big investor buys or sells
+ FollowMarket Cap$338.44M
Close$
Share Statistics
| Market cap | $338.44 Million |
|---|---|
| Enterprise Value | $336.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-21.5 |
| Beta | 0.74 |
| Outstanding Shares | 475,071 |
Return
| Return on Equity | -4165.92% |
|---|---|
| Return on Assets | -367.93% |
| Return on Invested Capital | -3423.86% |
Valuation & Multiples
| P/E Ratio | -0.16 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -27.08 |
| Enterprise Value to Net Income | -27 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 4.8 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Liminatus Pharma, Inc. Warrants
4 employees
CEO: Chris Kim Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.